rovalpituzumab tesirine rovat experimental antibodydrug conjugate targeting protein tumor originally developed stemcentrx purchased tested use smallcell lung cancer development terminated unsuccessful phase iii independent data monitoring committee found tahoe phase iii trial rovat shortened survival lung cancer patients compared soc chemotherapy topotecan prompting termination trial enrollment another phase iii trial meru demonstrated survival benefit phase ii trial using drug thirdline treatment relapsed refractory lung cancer showed objective response rate chemical structure tesirine drawn black consists pyrrolobenzodiazepine type dimer top actual anticancer agent structure cleaved enzyme detach anticancer agent antibody polyethylene glycol spacer maleimide linker attached cysteine antibodys rovalpituzumabs peptide backbone drawn blue rovalpituzumab molecule average two httpsenwikipediaorgwikirovalpituzumabtesirine